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In its most recent and fourth definition of myocardial infarc-tion (MI), the European Society of Cardiology has refined 
approaches to classify and differentiate MI.1 While higher 
sensitivity troponin assays have improved the identification 
of low-risk patients suitable for immediate discharge, detect-
ing, and treating minor cardiac damage may fail to result in 
better clinical outcomes.2 There is still a need for biomark-
ers that facilitate early rule-out/rule-in of clinically relevant 
MI. Using proteomics, we discovered that cMyBP-C (cardiac 
Rationale: Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), circular RNAs (circRNAs), and long 
noncoding RNAs (lncRNAs), are proposed novel biomarkers of myocardial injury. Their release kinetics have 
not been explored without confounding by heparin nor has their relationship to myocardial protein biomarkers.
Objective: To compare ncRNA types in heparinase-treated samples with established and emerging protein 
biomarkers for myocardial injury.
Methods and Results: Screening of 158 circRNAs and 21 lncRNAs in human cardiac tissue identified 12 circRNAs and 
11 lncRNAs as potential biomarkers with cardiac origin. Eleven miRNAs were included. At low spike-in concentrations 
of myocardial tissue, significantly higher regression coefficients were observed across ncRNA types compared with 
cardiac troponins and cMyBP-C (cardiac myosin-binding protein C). Heparinase treatment of serial plasma and 
serum samples of patients undergoing transcoronary ablation of septal hypertrophy removed spurious correlations 
between miRNAs in non-heparinase-treated samples. After transcoronary ablation of septal hypertrophy, muscle-
enriched miRNAs (miR-1 and miR-133a) showed a steeper and earlier increase than cardiac-enriched miRNAs (miR-
499 and miR-208b). Putative cardiac lncRNAs, including LIPCAR (long intergenic noncoding RNA predicting cardiac 
remodeling and survival), did not rise, refuting a predominant cardiac origin. Cardiac circRNAs remained largely 
undetectable. In a validation cohort of acute myocardial infarction, receiver operating characteristic curve analysis 
revealed noninferiority of cardiac-enriched miRNAs, but miRNAs failed to identify cases presenting with low troponin 
values. cMyBP-C was validated as a biomarker with highly sensitive properties, and the combination of muscle-enriched 
miRNAs with high-sensitive cardiac troponin T and cMyBP-C returned the highest area under the curve values.
Conclusions: In a comparative assessment of ncRNAs and protein biomarkers for myocardial injury, cMyBP-C 
showed properties as the most sensitive cardiac biomarker while miRNAs emerged as promising candidates to 
integrate ncRNAs with protein biomarkers. Sensitivity of current miRNA detection is inferior to cardiac proteins 
but a multibiomarker combination of muscle-enriched miRNAs with cMyBP-C and cardiac troponins could open 
a new path of integrating complementary characteristics of different biomarker types.  
Visual Overview: An online visual overview is available for this article. (Circ Res. 2019;125:328-340. DOI: 10.1161/
CIRCRESAHA.119.314937.)
Key Words: biomarkers ◼ cardiac myosin-binding protein C ◼ microRNAs ◼ myocardial infarction  
◼ RNA, long noncoding ◼ troponin
Comparative Analysis of Circulating Noncoding RNAs Versus 
Protein Biomarkers in the Detection of Myocardial Injury
Christian Schulte, Temo Barwari, Abhishek Joshi, Konstantinos Theofilatos, Anna Zampetaki,  
Javier Barallobre-Barreiro, Bhawana Singh, Nils A. Sörensen, Johannes T. Neumann, Tanja Zeller,  
Dirk Westermann, Stefan Blankenberg, Michael Marber, Christoph Liebetrau, Manuel Mayr
Circulation Research is available at https://www.ahajournals.org/journal/res DOI: 10.1161/CIRCRESAHA.119.314937
Editorial, see p 341 
Meet the First Author, see p 260
D
ow
nloaded from
 http://ahajournals.org by on July 25, 2019
Schulte et al  Circulating Biomarkers in Myocardial Injury  329
myosin-binding protein C) is released earlier upon myocardial 
ischemia than cardiac troponins3 and may contribute to a bet-
ter rule-out/rule-in classification of MI.4
Recently, noncoding RNAs (ncRNAs) have been im-
plicated as biomarkers of MI. MicroRNAs (miRNAs), long 
noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) 
are among the ncRNAs present in the circulation. Plasma 
and serum levels of muscle- and cardiac-enriched miRNAs 
increase markedly after MI.5,6 Besides miRNAs, lncRNAs, 
and circRNAs have attracted interest as potential biomark-
ers in cardiovascular disease. Levels of the long intergenic 
ncRNA predicting cardiac remodeling (LIPCAR) were re-
ported to predict adverse cardiac remodeling and death after 
MI.7 However, circRNAs as a different ncRNA type are less 
susceptible to RNase activity and may offer tissue specificity 
with >15 000 circRNAs being present in the human heart.8,9
Heparin, an anticoagulant commonly administered in the 
clinical setting of MI, is a major confounding factor for mea-
surements of ncRNAs by real-time polymerase chain reaction 
(qPCR). Few studies on the release of ncRNAs after MI used 
heparinase treatment to overcome this confounding effect by 
heparin, a prerequisite for comparative analysis of ncRNA 
and protein biomarkers. Moreover, while circulating levels of 
muscle- and cardiac-enriched miRNAs have been shown to 
correlate to troponins after MI, differences in the release of 
ncRNAs and novel protein biomarkers such as cMyBP-C have 
not been compared in the clinically most relevant setting of 
MI patients presenting early with low troponin values.
The objective of this study was to use heparinase treatment 
to establish the release kinetics of 3 different types of ncRNAs 
(miRNAs, lncRNAs, and circRNAs) in serial samples from 
patients undergoing transcoronary ablation of septal hypertro-
phy (TASH) as well as in patients with acute MI presenting 
with a wide range of hs-cTn (high-sensitive cardiac troponin) 
levels in the BACC study (Biomarkers in Acute Cardiac Care; 
n>2500 patients). The performance of ncRNAs was compared 
with hs-cTn and cMyBP-C as established and novel protein 
biomarkers of cardiac injury, respectively.
Methods
The authors declare that all supporting data are available within the 
article and its Online Data Supplement. Larger data sets, such as ar-
ray data, are available from the corresponding author on reasonable 
request.
RNA Extraction
Total RNA was extracted using the miRNeasy Mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s recommendations, 
with some modifications. In brief, 100 µL of serum or plasma were 
combined with 694.75 µL of Qiazol lysis reagent, 4 µL of diluted syn-
thetic Caenorhabditis elegans miR-39 (Cel-miR-39-3p) spike-in and 
1.25 µL carrier RNA from bacteriophage MS2 (Roche). After a brief 
incubation at room temperature, 140 µL of chloroform was added and 
the solution was mixed vigorously. Samples were then centrifuged at 
13500×g for 15 minutes at 4°C. Two hundred eighty microliters of 
the upper (aqueous) phase were transferred to a new tube and mixed 
with 1.5 volumes (420 µL) of 100% ethanol and applied to columns 
and washed according to the manufacturer’s protocol. Total RNA was 
eluted in 35 µL of nuclease-free H2O by centrifugation at 8500×g for 
1 minute at 4°C.
Heparinase Treatment
ncRNA Analyses
Before reverse transcription, the extracted RNA was treated with 
heparinase 1 from Flavobacterium heparinum (Sigma) according to 
Nonstandard Abbreviations and Acronyms
AUC area under the curve
BACC Biomarkers in Acute Cardiac Care
circRNA circular RNA
cMyBP-C cardiac myosin-binding protein C
hs-cTn high-sensitive cardiac troponin
LIPCAR long intergenic noncoding RNA predicting cardiac remodeling 
and survival
lncRNA long noncoding RNA
MI myocardial infarction
miRNA/miR microRNA
ncRNA noncoding RNA
NSTEMI non–ST-segment–elevation myocardial infarction
PEA proximity extension assay
ROC receiver operating characteristic
STEMI ST-segment–elevation myocardial infarction
TASH transcoronary ablation of septal hypertrophy
Novelty and Significance
What Is Known?
• High-sensitivity cardiac troponins are the gold standard biomarkers for 
myocardial infarction (MI).
• Noncoding RNAs (ncRNAs) have been reported as candidate biomark-
ers for MI.
• No study has compared different classes of ncRNAs with cardiac pro-
tein biomarkers.
What New Information Does This Article Contribute?
• Among ncRNAs, cardiac microRNAs (miRNAs) are the best biomarker 
candidates for MI.
• Current miRNA assays lack sensitivity for early detection of MI.
• cMyBP-C (cardiac myosin-binding protein C) shows promise as early 
biomarker for MI.
We performed a comparative analysis of ncRNAs and protein 
biomarkers in serial samples from patients undergoing induced 
myocardial injury or admitted with MI. Heparinase treatment 
is essential when evaluating ncRNAs in these clinical settings. 
MiRNAs were the most promising ncRNA type but current miRNA 
assays lack sensitivity for early detection of MI. Instead, cMyBP-
C showed favorable release kinetics as early rule-in/rule-out 
biomarker for MI. Measurements of cMyBP-C could offer some 
of the benefits of miRNAs, as evidenced by an earlier rise and 
faster decline after myocardial injury and a better baseline de-
tectability compared with cardiac troponins. A combination of 
cardiac protein and ncRNA biomarkers captures their different 
release kinetics, which might improve the diagnosis of MI.
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the following protocol: 5 µL of each sample were combined with 
1.25 µL heparinase, 0.25 µL of RNase inhibitor (Ribo Lock 40 
U/µL, Thermofisher) and 3.5 µL of heparinase buffer (pH 7.5) and 
thoroughly mixed, then incubated at 25°C for 3 hours. The samples 
were then immediately used for reverse transcription. For compari-
son, a buffer-only group was treated with heparinase buffer devoid 
of heparinase, which was incubated under the same conditions as 
the heparinase-treated samples. The untreated group received nei-
ther heparinase nor buffer, nor was it left for incubation, but instead 
was used for further reverse transcription together with the treated 
samples.
Proximity Extension Assay
cTnI was part of the organ damage panel offered by Olink (Uppsala, 
Sweden). Human plasma samples were treated by adding 0.1 U (con-
centration: 0.2 U/µL) of heparinase 1 per 1 µL of plasma. 0.5 µL of 
the heparinase solution was added per 1 µL of plasma. The mixture 
was then incubated for 1 hour at 30°C as previously described.10
Reverse Transcription
For reverse transcription, 2 different platforms (1) for miRNAs (miR-
CURY LNA RT kit [Exiqon]) and (2) for lncRNAs and circRNAs 
(SuperScript VILO MasterMix [Invitrogen]) were used. For further 
details see Online Data Supplement.
Real-Time PCR Assays
A list of primers used for qPCR detection and their sequence is 
provided in Online Table I. For further details see the Online Data 
Supplement.
RNA Quantification
In the analyses of raw quantification cycle (Cq) data, any measure-
ments beyond 35 cycles were considered undetectable. For details 
see the Online Data Supplement. In brief, the quantification for RNAs 
was performed as follows:
Analysis of miRNAs
In TASH samples as well as the MI cohort the delta-delta Cq method 
was used for relative quantification, using Cel-miR-39-3p as normal-
ization control. Quantification results were calibrated against the me-
dian of 3 identical replicates consisting of equal volumes from all 
TASH or all MI samples, respectively. Relative quantification was 
performed with Microsoft Excel, version 15.32 for MacOS. In the 
myocardial tissue in vitro spike-in experiment normalization was also 
performed using Cel-miR-39 spike-in. Calibration was performed us-
ing the median value of all samples per individual RNA assay to re-
move assay-related biases.
Analysis of circRNAs and lncRNAs
Calibration of circRNAs and lncRNAs in the TASH samples was 
performed against the median of all samples for each assay. In the 
myocardial tissue spike-in experiment, the same method was used. 
The relative quantity was calculated as described above for miRNAs.
Myocardial Tissue Spike-In Experiment
To assess the detectability of RNAs with cardiac origin, different 
amounts of human heart tissue were spiked into human plasma. For 
details see Online Data Supplement and Online Figure I.
Selection of ncRNAs
Two cardiac-enriched miRNAs (miR-208b-3p and miR-499a-5p), 
2 muscle-enriched miRNAs (miR-1 and miR-133a-3p), and 7 addi-
tional miRNAs were included in the analyses based on their good 
detectability in human plasma as noncardiac/nonmuscle counter-
parts. For circRNAs, we performed a microarray-based screening in 
4 pooled samples per time point of the TASH cohort (n=16 pooled 
samples; Arraystar Human Circular RNA Array, Arraystar INC, 
Rockville, MD). For details see Online Data Supplement. To com-
plement this screening, a literature search was performed. circRNAs 
were selected from 4 deep sequencing data sets reporting >15 000 cir-
cRNAs, of which 158 circRNAs were RNase R-treated and validated 
by qPCR. These 158 circRNAs plus their linear transcripts were first 
tested in 12 human cardiac tissue samples. For circRNAs with more 
than one transcript from the same gene, the one with the best detec-
tion based on Cq values was chosen. Only circRNAs with Cq values 
of <25 cycles that were derived from cardiac and muscle-associated 
genes (n=12) were included. lncRNAs were selected based on micro-
array screening of 33 045 lncRNAs in human plasma.7 Of these, 768 
lncRNAs showed differential plasma levels in patients developing 
heart failure after MI. Twenty-one lncRNAs with high signal inten-
sity were validated by qPCR. As for circRNAs, only lncRNAs with 
Cq values <25 (n=11) were selected for further analyses. A graphical 
depiction of the selection process including references is shown in 
Online Figure II.
Statistical Analyses
Tissue Spike-In Experiment
To enable comparisons of the relative expression values for ncRNAs 
and the absolute concentrations for protein biomarkers, relative quan-
tities have been calculated for all molecules by dividing their values 
with the median quantity for each molecule. Subsequently, linear re-
gression curves were calculated for all miRNAs, circRNAs, lncRNAs, 
and cardiac proteins to study their release kinetics by comparing the 
regression curves slopes. All R2 values were >0.9, therefore, the used 
linear model provides a good fit to the data. Next, the slopes of the 
regression curves of the 3 molecules with the highest scores were 
selected from each category; for miRNAs: miR-133a, miR-208b, 
and miR-499; for circRNAs: circALPK2, circMYBPC3, and circ-
SLC8A1; for lncRNAs: lncDANCR, lncH19, and lncRNACOX2; 
and for proteins: hs-cTnT, hs-cTnI, and cMyBP-C. Mann-Whitney U 
tests11 were used to perform pairwise statistical comparisons between 
the slopes of proteins and ncRNAs.
TASH Cohort
To study the release kinetics of proteins and ncRNAs at 1 hour after 
TASH, absolute protein measurements and relative RNA measure-
ments were both transformed into relative values on the same scale 
by dividing each value by the overall maximum value of the single 
biomarker across all time points. The data for each molecule and each 
patient were curve-fitted using linear regression and slopes of the 
curves were calculated. Mann-Whitney U tests were used to perform 
pairwise statistical comparisons between the slopes of the regression 
curves of protein and ncRNA molecules.
BACC Study
Analyses to study release kinetics after acute MI were performed a-
nalogous to the TASH cohort for the first hour after hospital presenta-
tion. Correlation analyses of biomarkers in the acute MI cohort were 
performed with Graph Pad Prism 7.0d for MacOS. Nonparametric 
Spearman correlation was used because none of the biomarkers 
were normally distributed. P values in the correlation analyses were 
2-tailed, and approximate values were calculated.
Receiver Operating Characteristic Analyses
For training and testing regression models for predicting the time 
from onset of MI combining miRNAs and proteins, we used a hy-
brid of a heuristic algorithm and Support Vector Regression models 
(details are provided in the Online Data Supplement).
Results
Detectability of ncRNAs in Human Plasma
To compare detectability of different ncRNAs human myo-
cardial tissue was spiked into plasma of healthy volunteers 
at defined concentrations of 0.25 µg to 25µg/100 µL plasma 
(Online Figure I). Based on published data, we selected 158 
circRNAs and 21 lncRNAs that were reported as abundant 
in human myocardium (for details see Methods section and 
Online Figure II). circRNAs associated with cardiac-specific 
proteins, such as cTnT, cTnI, and cMyBP-C, were among the 
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least well-detectable circRNAs in plasma (data not shown). 
Muscle- (miR-1 and miR-133a) and cardiac-enriched miRNAs 
(miR-208b and miR-499) were chosen for comparison. These 
4 miRNAs showed comparable regression curves to cardiac 
circRNAs (circSLC8A1, circMyBPC3, and circALPK2) and 
lncRNAs (lncLIPCAR and lncH19 lncuc004.cov4; Figure 1A, 
Online Figures III, IV, and V). Levels of other miRNAs re-
mained unaltered on spiking human myocardial tissue into 
plasma (Online Figure VI). Next, ncRNA spike-in results 
were compared with measurements of established and novel 
cardiac protein biomarkers as previously described12 (Online 
Figure VII). While ncRNAs demonstrated a continuous, linear 
dose-response curve across all spike-in concentrations, mea-
surements of cardiac proteins (hs-cTnT, hs-cTnI, and cMyBP-
C) remained below their regression curve at low spike-in 
concentrations (0.25 µg and 2.5 µg/100 µL plasma; Figure 1A, 
colored boxes). At low spike-in concentrations, ncRNA re-
gression curves were steeper compared with cardiac protein 
biomarkers (Figure 1B). Curve fitting analyses for low spike-
in concentrations returned significantly higher regression 
coefficients for ncRNAs (Figure 1C, Mann-Whitney U test 
for comparison against cardiac protein biomarkers: miRNAs 
P<0.0001, fold-change 2.6; circRNAs P=0.0028, fold-change 
2.8; and lncRNAs P=0.0028, fold-change 1.6).
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Figure 1. Myocardial tissue spike-in. A, Linear regression curves of each of the 3 noncoding RNA (ncRNA) classes with the highest coefficient of 
determination (R2) values. At low spike-in concentrations, the measured protein concentrations were markedly below the regression curve (colored boxes). B, 
Linear regression curves of all biomarker types, combining the single biomarkers from A per class. ncRNAs showed steeper regression curves compared with 
protein biomarkers. C, At low spike-in concentrations, significantly higher regression coefficients, indicating higher sensitivity, were observed for all ncRNA 
types compared with proteins. cMyBP-C indicates cardiac myosin-binding protein C; hs-cTnI, high-sensitive cardiac troponin I; and hs-cTnT, high-sensitive 
cardiac troponin T; and lncRNA, long noncoding RNA. ***P<0.0001; *P<0.0028 (Mann-Whitney U test).
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Confounding by Heparin in ncRNA Analysis
The derangements of ncRNA biomarker measurements after 
heparin administration can be addressed by heparinase treat-
ment as demonstrated in 2 examples: First, human plasma 
was spiked with 10 IU of heparin per 1 mL plasma. Heparin 
reduced the detectability of the exogenous spike-in control 
Cel-miR-39 and endogenous miRNAs resulting in elevated 
raw Cq values, which was reversed by heparinase treatment 
(Figure 2A). Second, we assessed samples from a cohort of 
patients undergoing TASH,13 where the exact time points of 
myocardial injury and heparin administration were known, 
and samples were obtained at baseline before myocardial in-
jury. We evaluated plasma miRNA levels before and 1 hour, 8 
hours, and 24 hours after induced myocardial injury in TASH 
patients (n=16). In non-heparinase-treated samples, we dis-
covered a dense miRNA correlation network, which consists 
of spurious correlations between miRNAs independent of their 
cellular origin. This observation contradicts the well-known 
cell- and tissue-associated expression of miRNAs (Figure 2B). 
Notably, liver-specific miR-122 and red blood cell-enriched 
miR-486 appeared in the same cluster area. Heparinase treat-
ment resolved the clustering of the network removing spuri-
ous correlations between miRNAs in non-heparinase-treated 
samples. Thus, the distinct cellular origins of plasma miRNAs 
became readily apparent: as visualized in Figure 2B, the clus-
tering shows liver miR-122 and red blood cell miR-486 in sep-
arate cluster areas from previously reported platelet-enriched 
miRNAs (miR-126, miR-223, and miR-191).
Release Kinetics of ncRNAs After TASH
To assess the release of ncRNAs after myocardial injury, serial 
samples were obtained from patients undergoing TASH.14 On 
A
B
Figure 2. Heparin effect on selected microRNAs (miRNAs) and results after heparinase treatment. A, Human plasma samples were treated with heparin 
after blood was drawn, then miRNA expression was measured (blue). The measurements were repeated in the same samples after they were treated with 
heparinase (red) or with a buffer solution lacking heparinase (gray). B, Clustering networks of miRNAs in the transcoronary ablation of septal hypertrophy 
(TASH) cohort: before heparinase treatment the analyzed miRNAs showed a dense correlation network. Heparinase treatment resolved this clustering of 
miRNAs, removing spurious correlations between miRNAs in non-heparinase-treated TASH samples. The distinct cellular origin of miRNAs, ie, liver-specific 
miR-122 vs red blood cell-associated miR-486, became more readily apparent. Coeff. of variat. indicates coefficient of variation.
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heparinase treatment, the release of ncRNAs was compared 
with hs-cTnT and cMyBP-C at baseline, 1 hour, 8 hours, and 
24 hours after induced myocardial injury. The clinical char-
acteristics of the TASH patients were reported previously.14 
Plasma and serum from 16 patients at 4 time points were used 
for comparative analyses of the release of muscle- (miR-1 and 
miR-133a; Figure 3A) and of cardiac-enriched miRNAs (miR-
208b and miR-499; Figure 3B), circRNAs (circSMARCA and 
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Figure 3. Noncoding RNAs (ncRNAs) after transcoronary ablation of septal hypertrophy (TASH). Relative plasma levels as well as raw Cq values for 
muscle-enriched (A) and cardiac-enriched (B) microRNAs (miRNAs) as well as circular RNAs (circRNAs) (C) and long noncoding RNA (lncRNAs) (D) after 
TASH for time points before (0 h) and after myocardial injury (1 h, 8 h, and 24 h). Dotted line indicates the detectability threshold; Cq values above 35 
were considered as undetectable. Of particular interest is the time course of the first hour after TASH with respect to biomarker sensitivity (colored boxes). 
Depicted are median values, error bars indicate interquartile range.
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circPCMTDL; Figure 3C), and lncRNAs (lncLIPCAR and 
lncH19; Figure 3D). These circRNAs and lncRNAs were cho-
sen for their best detectability in plasma and serum. Unlike 
muscle-enriched miRNAs, the 2 cardiac-enriched miRNAs 
were undetectable at baseline. MiR-208b became detectable 
at 1 hour after TASH. For miR-499, detectable levels were 
only reached at 8 hours after TASH. Neither mitochondrial 
lncRNA LIPCAR nor nucleus-derived lncRNA H19 changed 
after TASH (Figure 3D). Thus, LIPCAR and lncRNA H19 lev-
els are not of cardiac origin. Unlike other ncRNA classes, car-
diac circRNAs showed poor detectability at baseline and after 
TASH (Figure 3C), despite the fact that these circRNAs were 
readily detectable in cardiac tissue (Online Figure VIII). An 
additional circRNA microarray screening of 13 617 circRNAs 
performed at all 4 time points did not return any significantly 
dysregulated circRNAs after TASH (Online Figure IX).
Comparison of Cardiac Protein Versus ncRNA 
Biomarkers in TASH
Figure 4 depicts the time course of serum levels of cardiac 
protein biomarkers (hs-TnT and cMyBP-C; Figure 4A) and 
circulating muscle-enriched miRNAs after TASH (miR-1 and 
miR-133a; Figure 4B). As reported previously,15 cMyBP-C 
levels peaked before hs-TnT. Similarly, muscle-enriched miR-
NAs (miR-1 and miR-133a) peaked earlier than cardiac pro-
tein biomarkers. When the measurements of cardiac proteins 
and the 2 muscle-enriched miRNAs, miR-1 and miR-133a, 
were expressed as proportions of the maximum detected 
value (Figure 4C), cMyBP-C showed a significantly higher 
regression coefficient compared with hs-cTnT (P<0.0001, 
Mann-Whitney U test; Figure 4D). Similarly, higher regres-
sion coefficients were observed for muscle-enriched miRNAs 
compared with cardiac protein biomarkers within the first 
hour after induced myocardial injury (Mann-Whitney U test; 
hs-TnT versus miR-1 P<0.0001, hs-TnT versus miR-133a 
P<0.0001, cMyBP-C versus miR-1 P=0.0091, and cMyBP-C 
versus miR-133a P=0.0088; Figure 4D).
Circulating miRNAs and proteins were measured by qPCR 
and ELISA, respectively. To rule-out that the different assay 
methodology impacts on the observed release kinetics, cTnI 
was assessed using a proximity extension assay (PEA). The 
PEA combines dual antibody-based detection with qPCR-
based quantification. While the PEA for cTnI was less sen-
sitive compared with hs-cTnT, both assays revealed a similar 
temporal profile for the cTn release after TASH (Figure 4C). 
The PEA measurements of cTnI were not affected by heparin 
(Online Figure X) because of the minute amount of sample 
input required compared with miRNA measurements (1 µL of 
plasma for cTnI versus 100 µL for miRNAs).
Comparison of miRNAs, cMyBP-C, and Troponins 
in Patients With Acute MI
To compare miRNA kinetics in patients with acute MI, we 
analyzed plasma samples from a carefully selected subcohort 
A
B
C
D
Figure 4. Noncoding RNAs (ncRNAs) and protein biomarkers after transcoronary ablation of septal hypertrophy (TASH). A, Levels of cardiac protein 
biomarkers in the TASH cohort. B, Levels of muscle-enriched miRNAs in the TASH cohort. C, Transformation of absolute protein quantification measures 
and relative miRNA quantification measures plus additional relative measures by proximity extension assays (PEA, Olink) to the same scale by dividing each 
value by the maximum value of each biomarker. D, Slope statistics on the relative expression of miRNAs after transformation according to panel B revealed 
significant differences in the regression coefficients between muscle-enriched miRNAs (miR-1 and miR-133a) and protein biomarkers for the first hour after 
TASH (time point 0 and 1h). ***P<0.0001; *P<0.01 (Mann-Whitney U test) relative to the maximum value of each biomarker. Panels A–C show median values, 
error bars indicate interquartile range. TnI-PEA denotes cardiac troponin I as measured by PEA.
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(n=83) of the BACC study,16 focusing on patients with initially 
low hs-cTnT levels which show a steep increase within the first 
hour after hospital presentation (Online Table II). Samples were 
taken on admission, 1 hour and 3 hours thereafter in 38 acute 
MI patients. 45 patients with noncardiac chest pain served as 
controls. The plasma levels of muscle- and cardiac-enriched 
miRNAs strongly correlated with concentrations of hs-cTnT, 
hs-cTnI, and cMyBP-C (Figure 5). Correlations were stronger in 
patients with ST-segment–elevation MI (STEMI, n=20) than in 
patients with non–ST-segment–elevation myocardial infarction 
(NSTEMI, n=18; Online Figure XI). As expected, given their 
cardiac enrichment, the highest correlation with hs-cTnT was 
observed for the 2 cardiac-enriched miRNAs, miR-208b, and 
miR-499 (r=0.81 and r=0.88, respectively, P<0.0001), which 
is as high a correlation level as between hs-cTnT and cMyBP-
C and hs-cTnT and hs-cTnI (r=0.87 and r=0.83, respectively, 
P<0.0001). The correlation was substantially weaker for the 2 
muscle-enriched miRNAs, miR-1, and miR-133a (r=0.67 for 
both, P<0.0001). Correlations of miRNAs with cMyBP-C were 
comparable with correlations of miRNAs with hs-cTnT.
Because the diagnosis of acute MI was adjudicated based 
on hs-cTnT, hs-cTnI was measured.16 Data for hs-cTnI were 
comparable with hs-cTnT (Online Figure XIIA and XIIB). 
At time point 0 and 1 hour, one sample was below the lower 
limit of detection for hs-cTnT for each time point, while hs-
cTnT was detectable in all MI patients at 3 hours. In con-
trast, all miRNAs showed numerous undetectable values in 
the MI group (Figure 6A). Again, this was more pronounced 
in NSTEMI patients than in STEMI patients (Online Figure 
XIII). Hs-cTnT was above the lower limit of detection in 85% 
of the control patients (n=45), while cMyBP-C levels were 
above the lower limit of detection in 100% of the measurements, 
including control patients (Online Figures XIIC and XIV).
Next, miRNA levels were reported for defined hs-cTnT 
groups (Figure 6B). Only at high hs-cTnT concentrations 
(>1000 ng/L), miRNAs were detectable in all MI patients. 
At low-positive hs-cTnT levels (comprising hs-cTnT levels 
between 21 and 50 ng/L), miR-1, miR-133a, miR-208b, and 
miR-499 were detectable in 47%, 87%, 7%, and 13% of pa-
tients, respectively. In patients with hs-cTnT concentrations 
below 10 ng/mL, miR-208b and miR-499 remained below the 
detection threshold (Cq of >35) whereas miR-1 and miR-133a 
were detectable in 39% and 64% of patients, respectively. To 
validate this finding, we included an additional group of 19 
carefully selected MI patients with hs-cTnT levels of <1000 
ng/L at all 3 time points (n=57 samples, Online Table III). In 
an attempt to maximize detectability, we doubled the input of 
RNA for the RT-qPCR reaction. The rise in miR-1, miR-133a, 
miR-208b, and miR-499, however, was mainly detectable at 
hs-cTnT levels >50 to 100 ng/L (Online Figure XV).
Analogous to the TASH results, miR-1 (44%) and miR-
133a (63%) were also more readily detectable in the control 
group compared with miR-208b (0%) and miR-499 (10%; 
Online Figure XIV). cMyBP-C was detectable in all control 
and MI samples. Confirming the results from the TASH pa-
tients, in the MI cohort, cMyBP-C showed a steeper increase 
shortly after hospital presentation than hs-cTnT with yet 
smaller coefficients of variation at all time points in the MI co-
hort (Figure 7A). Curve fitting analysis revealed significantly 
higher regression coefficients for cMyBP-C than for hs-cTnT 
and muscle and cardiac miRNAs (Figure 7B).
Comparison of Receiver Operating Characteristic 
Analyses Based on the TASH and MI Cohorts
When comparing patients before the TASH procedure with 
any of the time points after (1 hour, 8 hours, and 24 hours), 
both miRNAs-208b and -499 showed a higher predictive value 
(area under the curve [AUC], 0.934 and 0.948, respectively) 
than hs-cTnT (0.918) for the detection of myocardial injury 
(Figure 8A, Online Figure XVI and Table IV). The combina-
tion of hs-cTnT with miR-208b or miR-499 improved AUC 
Figure 5. Correlation of cardiac biomarkers in acute myocardial infarction (MI). All analyzed biomarkers are highly correlated. Cardiac-enriched 
microRNAs (miRNAs) correlate better with hs-cTnT (high-sensitive cardiac troponin T) and among each other than muscle-enriched miRNAs. Depicted are 
regression coefficients; P for all combinations <0.0001. CK indicates creatine kinase; CK-MB, creatine kinase muscle/brain; cMyBP-C, cardiac myosin-
binding protein C; hs-cTnI, high-sensitive cardiac troponin I; and TnI-PEA, cardiac troponin I as measured by a proximity extension assay (PEA, Olink).
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values to 0.943 and 0.957, respectively. A combination of 
both cardiac-enriched miRNAs offered no further improve-
ment in the predictive value. AUC values for miR-1 and miR-
133a were lower (0.824 and 0.790, respectively) despite their 
higher sensitivity. cMyBP-C was the cardiac biomarker with 
the highest predictive power (0.967).
Next, the MI cohort was used as an independent validation 
cohort for the predictive analytics from TASH. Thus, the most 
promising regression models of the different combinations of 
proteins and miRNAs were applied to the MI cohort. When 
comparing control patients with acute MI patients at any of 
the time points (0 hour, 1 hour, and 3 hours), both miRNAs-
208b and -499 showed similar power (AUC values of 0.920 
and 0.921, respectively) as hs-cTnT (0.925) for the pre-
diction of MI. This result is comparable to the receiver op-
erating characteristic (ROC) analyses in the TASH cohort. 
AUC values for miR-1 and miR-133a were lower (0.825 and 
0.734, respectively) despite their higher sensitivity in plasma, 
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Figure 6. MicroRNA (miRNA) raw expression data in the myocardial infarction (MI) cohort. A, Raw Cq values of miRNAs for control patients (Ctr) 
and MI patients according to time of admission to hospital (0 h on presentation at hospital, 1 h and 3 h after presentation). At every time point, there were 
undetectable values (Cq>35) for each miRNA. B, miRNA raw Cq values corresponding to different ranges of hs-cTnT (high-sensitive cardiac troponin T) 
concentrations (ng/L). Only for hs-cTnT levels above 1000 ng/L all miRNAs showed 100% detectability. Black dotted line denotes lower limit of detection 
(Cq>35).
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demonstrating the lack of cardiac specificity of muscle-en-
riched miRNAs (Figure 8B, Online Figure XVII and Table V). 
The highest AUC value in TASH was observed for cMyBP-C 
(0.967), while in the MI cohort, the best performance in the 
ROC analysis was observed for the combination of hs-TnT, 
cMyBP-C, and muscle-enriched miRNAs (0.969).
Finally, cases of STEMI and NSTEMI (excluding 
NSTEMI type 2) were assessed separately to explore different 
causes of myocardial injury. The ROC analyses presented in 
Figure 8C and 8D indicate that the performance of the diag-
nostic models is better in STEMI patients. The performance 
in the NSTEMI group was inferior to both STEMI and all MI 
cases. Importantly, the ranking of biomarker performance was 
consistent in all 3 comparisons, independent of the overall 
performance of the model.
Discussion
Thus far, most attention has focused on miRNAs although new 
classes of ncRNAs have been identified in the circulation.17,18 
In addition to miRNAs, we assessed the potential of selected 
lncRNAs and circRNAs to serve as biomarkers of myocardial 
injury. To the best of our knowledge, no study has directly 
compared these classes of ncRNAs with cardiac protein bio-
markers. Using heparinase-treated samples, we assessed the 
release of ncRNAs after TASH in a well-controlled context 
of cardiac injury and of miRNAs in the most relevant clinical 
setting of MI cases presenting with low initial troponin values.
Heparinase Treatment to Overcome Confounding 
by Heparin
Heparin inhibits qPCR-based ncRNA quantification.19 
Confounding by heparin is evidenced by decreased detect-
ability, higher variation, or spurious correlations of ncRNA 
measurements. Apart from endogenous miRNAs, heparin 
predominantly affects the quantification of the exogenous 
Cel-miR-39 spike-in control. As pointed out previously,20 the 
inter-sample deviation of Cel-miR-39 measurements should 
be <1 cycle. However, within the first hour after administra-
tion of the heparin bolus, the detectability of Cel-miR-39 de-
creases by approximately 3 cycles. This variability is related 
to the half-life of heparin in the circulation. Most publications 
assessing miRNAs in samples from patients with MI failed 
to address this issue (Online Table VI). If unnoticed, heparin-
induced suppression of the Cel-miR-39 normalization control 
results in artificially higher levels of endogenous miRNAs, 
especially within the first hour after heparin administration 
(Figure 2B). Heparinase treatment can overcome the con-
founding introduced by heparin in samples from MI patients.21 
This is the first time that heparinase treatment was performed 
on a clinical MI cohort before ncRNA quantification. Our 
analyses of miRNAs in MI patients returned substantially 
higher correlation coefficients with cardiac troponins than 
previous publications that did not use heparinase.21
NcRNAs and Protein Biomarkers in Myocardial 
Injury
Assays for cTnI and cTnT are the gold standard for detection of 
myocardial injury.22,23 The excellent sensitivity of these assays 
is the result of decades of optimization.24,25 Using proteomics, 
we have recently identified a new cardiac biomarker, cMyBP-
C, which may allow for an earlier detection and better rule-in/
rule-out of MI.3,4 In our assessment, cMyBP-C detected myo-
cardial injury with a higher accuracy than hs-cTnT and hs-cTnI 
in the controlled TASH model. This finding is supported by a 
steeper rise within the first hour after TASH and in all time in-
tervals (0–1 hour and 1–3 hours) in the MI cohort. cMyBP-C 
showed a higher detectability among control patients compared 
with hs-cTnT (100% versus 85%, respectively). However, ROC 
analysis in the validation cohort of MI revealed lower AUC 
for cMyBP-C compared with hs-cTnT (0.898 versus 0.925). 
This finding is most likely attributable to 2 factors: First, as op-
posed to TASH, the diagnosis of MI was adjudicated based on 
hs-cTnT; and second, the selection of the MI patients from the 
BACC cohort was determined by initially low and then steeply 
rising hs-cTnT levels. Importantly, cMyBP-C has been reported 
as more sensitive compared with cTn.4 This is supported by our 
finding that cMyBP-C shows a steeper rise in the first hour after 
onset of myocardial injury. The better detectability of cMyBP-
C in controls also suggests that cMyBP-C might be a biomarker 
for cardiac disease in non-acute settings.
In addition to cardiac proteins, miRNAs offer a new 
opportunity for the detection of myocardial injury. The 
A B
Figure 7. Release kinetics of cardiac protein biomarkers and curve fitting in myocardial infarction (MI) cohort. A, cMyBP-C (cardiac myosin-binding 
protein C) rose more quickly after onset of MI compared with hs-cTnT (high-sensitive cardiac troponin T) with still a smaller coefficient of variation (values 
depicted are median with interquartile range). B, Curve fitting analysis of the first hour after hospital presentation revealed significantly higher regression 
coefficients for cMyBP-C than all other biomarkers. ns indicates not significant (Mann-Whitney U test). ****P<0.0001; ***P=0.0002. Ctr indicates control 
patients; and miR; microRNA.
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muscle-enriched miRNAs, miR-1 and miR-133a, have been 
implicated as markers for cardiac injury but are not specific 
for the heart. In contrast, miR-499 and miR-208a/b have 
higher cardiac specificity but are less abundant in heart and 
in plasma.26 By spiking plasma with human myocardial tis-
sue, we demonstrated that qPCR assays for ncRNAs detect the 
presence of smaller amounts of myocardial tissue than cardiac 
proteins. The regression curves for ncRNAs compared with 
protein biomarkers indicated a potentially higher sensitivity of 
qPCR-based measurements of ncRNAs. In a tightly controlled 
clinical setting of induced myocardial injury after TASH, 
muscle- and cardiac-enriched miRNAs showed an earlier 
rise than hs-cTnT, which was similar to the release kinetics 
of cMyBP-C (Figure 3A and 3B and Figure 4A and 4B). To 
exclude that this difference derives from the mode of measure-
ment, we also performed additional cTnI measurements with 
PEA, which combines antibody-based detection with qPCR-
based quantification. Another important aspect for biomarker 
performance is the clearance of cardiac proteins and miRNAs 
from the circulation. Similar to cMyBP-C, miRNA levels 
peaked at 8 hours and declined or plateaued thereafter. In con-
trast, hs-cTnT concentrations were still rising at 24 hours af-
ter TASH. While single miRNAs failed to outperform cardiac 
protein biomarkers in detecting early MI, a multibiomarker 
combination of 2 muscle-enriched miRNAs with hs-cTnT and 
cMyBP-C returned the highest predictive power for the detec-
tion of MI in a subcohort of the BACC study. This was con-
sistent across different causes of myocardial injury (STEMI 
and NSTEMI type 1). While the biomarker selection and their 
ranking did not change, the overall performance of the predic-
tion model was largely dependent on infarct severity.
Cardiac- and Muscle-Enriched miRNAs
Although cardiac and muscle-enriched miRNAs have been pre-
viously studied as biomarker candidates for myocardial injury, 
our findings in heparinase-treated samples highlight important 
aspects that have, to our knowledge, not been addressed so far. 
First, the muscle-enriched miRNAs, miR-1 and miR-133a, are 
more readily detectable at baseline, while miR-208 and -499 
reach detectable levels only at higher corresponding hs-cTnT 
Figure 8. Receiver operating characteristic (ROC) analysis comparing predictive power of protein and microRNA (miRNA) biomarkers. A, 
Transcoronary ablation of septal hypertrophy (TASH) cohort. B, Myocardial infarction (MI) cohort with subanalysis for (C) ST-segment–elevation myocardial 
infarction (STEMI) patients. D, Non–ST-segment–elevation myocardial infarction (NSTEMI) patients. Blue color for proteins, red for miRNAs, white for 
combinations of 2 or more biomarkers. The biomarkers are ranked from left to right (highest to lowest area under the curve [AUC] value). The intensity of the 
blue and red color increases with increasing AUC values.
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concentrations.5 However, cardiac-enriched miRNAs are more 
specific for myocardial injury. They correlate best with hs-cTnT 
and predict myocardial injury better in the TASH cohort and as 
good as hs-cTnT in the MI cohort. This is consistent with previ-
ous reports of miR-208 and miR-499 being elevated in plasma 
only in cases of MI or myocardial injury, while miR-1 and miR-
133a can rise in different cardiac pathologies.6,27 In a ROC a-
nalysis of the TASH cohort, cardiac-enriched miRNAs returned 
higher AUC values than muscle-enriched miRNAs. Second, 
cardiac miRNA measurements in patients with MI reached the 
detection limit of Cq<35 cycles only at high hs-cTnT values 
(>50–100 ng/L). Thus, miRNAs failed to identify patients with 
MI that initially present with low or negative cTn values. A crit-
ical evaluation of publications is required as higher thresholds 
of detection may have been used in some studies and confound-
ing by heparin was not taken into consideration (Online Table 
VI). Given their favorable release kinetics, this shortcoming 
of cardiac miRNA biomarkers might be attributed to the low 
miRNA yield from plasma, miRNA degradation after release 
into circulation and inadequate detection methods compared to 
high-sensitivity protein assays.
LncRNAs
LncRNAs are a heterogeneous group of RNAs with >200 
nucleotides in length.28 Unlike miRNAs, lncRNAs are mainly 
located within the nucleus or in mitochondria.7,29 Regardless, 
lncRNAs are readily detected in the circulation, suggesting 
some protection against RNase-mediated degradation similar to 
plasma miRNAs.28 LIPCAR was found to predict adverse car-
diac remodeling and death in the aftermath of MI.7 LIPCAR 
has been proposed as a biomarker of cardiac disease. However, 
the cardiac origin of this lncRNA in plasma has not been con-
firmed. In our experiments, LIPCAR showed a comparable 
regression curve to cardiac miRNAs in the myocardial tissue 
spike-in and good detectability in plasma. LIPCAR levels, 
however, did not increase after TASH, refuting a cardiac origin. 
Because LIPCAR is of mitochondrial origin and ubiquitously 
expressed, its rise in plasma may be explained by a release of 
mitochondria from blood cells rather than cardiac injury.30
CircRNAs
CircRNAs are expressed in a tissue- and developmental-spe-
cific manner.9 They can either emerge from exons or introns of 
pre-mRNA and are products of alternative splicing known as 
backsplicing.8 circRNAs have diverse functions31,32 and are tissue-
specific.33 Sequencing data revealed the presence of >15 000 cir-
cRNAs in the human heart, some in high abundance.9 circRNAs 
have previously been implicated in MI-related apoptosis.34 The 
majority of circRNAs are located in the cytoplasm,35 which in-
creases the probability of their early release upon tissue damage. 
circRNAs have been described as circulating biomarkers in the 
field of oncology.36 Our study is the first to assess circRNAs as 
biomarkers in acute MI. circRNAs in plasma showed poor detect-
ability despite high abundance in cardiac tissue. Also, circRNAs 
did not show a rise in plasma after myocardial injury. While cir-
cRNAs are supposedly less prone to degradation compared with 
their linear transcripts,37 this may differ in the circulation where 
circRNAs have been described as having a short half-life.37 Thus, 
cardiac circRNAs were not well detectable in plasma and serum.
Conclusions
In summary, heparinase treatment is essential when evaluating 
ncRNAs in clinical settings. Among ncRNAs, cardiac miR-
NAs remained the best predictor for the diagnosis of acute MI. 
In serial samples from TASH and acute MI patients, cardiac 
miRNAs showed comparable AUC values to hs-cTnT and the 
additional use of muscle-enriched miRNAs combined with hs-
cTnT and cMyBP-C returned the highest AUC for MI, point-
ing out their potential in combined protein/ncRNA biomarker 
approaches. However, miRNA sensitivity proved to be well 
below hs-cTnT, arguing against their clinical application at 
the current stage of methodological advances. Thus, analyses 
in larger cohorts seem warranted once technological advanc-
es offer better sensitivity. Future miRNA assays also require 
faster, automated quantification if miRNAs were to be used in 
a clinical setting for complementing protein biomarkers. With 
regards to cardiac proteins, measurements of cMyBP-C could 
offer some of the benefits of miRNAs, as evidenced by an ear-
lier rise and faster decline after myocardial injury and a better 
baseline detectability compared with cardiac troponins.
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